Clozapine antipsychotic polypharmacy: audit of use and patient monitoring
| Autor: | Sheila Howitt, Angela MacManus, Sam Wilson, Blessing Okpo, John S. Callender, Ross J Hamilton |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Polypharmacy
medicine.medical_specialty Remote patient monitoring business.industry medicine.medical_treatment Audit 030227 psychiatry 03 medical and health sciences Psychiatry and Mental health 0302 clinical medicine Emergency medicine medicine Antipsychotic Medications 030212 general & internal medicine Antipsychotic business Psychiatry Clozapine medicine.drug |
| Zdroj: | The Psychiatrist. 37:322-325 |
| ISSN: | 1758-3217 1758-3209 |
| DOI: | 10.1192/pb.bp.112.040352 |
| Popis: | Aims and methodWe audited prescribing within our area to ascertain how widespread the practice of antipsychotic polypharmacy using clozapine was, and whether it was being carried out within existing standards, including those of high-dose monitoring when required.ResultsData on 169 patients were reviewed in year one, rising to 193 in year three. Around 30% of patients on clozapine received additional antipsychotic medication. A disturbingly low proportion of patients on clozapine whose antipsychotic polypharmacy brought them into the high-dose range were being monitored appropriately after three audit cycles (the proportion rose from 10% in cycle 1 to 28% in cycle 3). A wide range of additional antipsychotic medications was used.Clinical implicationsClozapine antipsychotic polypharmacy was prevalent at just below a third of all patients in this review. Prescribers should be alert to the fact that clozapine antipsychotic polypharmacy can push patients into the high-dose range and ensure appropriate monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|